{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:41:55Z","timestamp":1785519715700,"version":"3.56.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s12325-024-03099-y","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T10:47:20Z","timestamp":1738234040000},"page":"1462-1483","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness and Safety in Patients with Non-Valvular Atrial Fibrillation Who Switched from Warfarin to Direct Oral Anticoagulants in Medicare Population"],"prefix":"10.1007","volume":"42","author":[{"given":"Nipun","family":"Atreja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anandkumar","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amiee","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Hagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abimbola","family":"Michael-Asalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Deitelzweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"issue":"10","key":"3099_CR1","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391.","journal-title":"N Engl J Med"},{"key":"3099_CR2","unstructured":"Healthline. What is nonvalvular atrial fibrillation? 2023 [updated 5\/19\/2023. Available from: https:\/\/www.healthline.com\/health\/atrial-fibrillation\/nonvalvular."},{"issue":"12","key":"3099_CR3","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/europace\/euu178","volume":"16","author":"M Molteni","year":"2014","unstructured":"Molteni M, Polo Friz H, Primitz L, Marano G, Boracchi P, Cimminiello C. The definition of valvular and non-valvular atrial fibrillation: results of a physicians\u2019 survey. Europace. 2014;16(12):1720\u20135.","journal-title":"Europace"},{"issue":"6","key":"3099_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40256-017-0244-1","volume":"17","author":"AM Gilligan","year":"2017","unstructured":"Gilligan AM, Gandhi P, Song X, Wang C, Henriques C, Sander S, et al. All-cause, stroke-, and bleed-specific healthcare costs: comparison among patients with non-valvular atrial fibrillation (NVAF) newly treated with dabigatran or warfarin. Am J Cardiovasc Drugs. 2017;17(6):481\u201392.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"3099_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.15420\/ecr.2017:11:2","volume":"12","author":"S Julia","year":"2017","unstructured":"Julia S, James U. Direct oral anticoagulants: a quick guide. Eur Cardiol. 2017;12(1):40\u20135.","journal-title":"Eur Cardiol"},{"issue":"25","key":"3099_CR6","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1016\/j.jacc.2020.04.067","volume":"75","author":"P Osmancik","year":"2020","unstructured":"Osmancik P, Herman D, Neuzil P, Hala P, Taborsky M, Kala P, et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. J Am Coll Cardiol. 2020;75(25):3122\u201335.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"3099_CR7","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1056\/NEJM199608223350802","volume":"335","author":"EM Hylek","year":"1996","unstructured":"Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335(8):540\u20136.","journal-title":"N Engl J Med"},{"issue":"3","key":"3099_CR8","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s11239-013-0899-7","volume":"35","author":"M Shoeb","year":"2013","unstructured":"Shoeb M, Fang MC. Assessing bleeding risk in patients taking anticoagulants. J Thromb Thrombolysis. 2013;35(3):312\u20139.","journal-title":"J Thromb Thrombolysis"},{"issue":"9","key":"3099_CR9","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/pds.1556","volume":"17","author":"AB Platt","year":"2008","unstructured":"Platt AB, Localio AR, Brensinger CM, Cruess DG, Christie JD, Gross R, et al. Risk factors for nonadherence to warfarin: results from the IN-RANGE study. Pharmacoepidemiol Drug Saf. 2008;17(9):853\u201360.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"3099_CR10","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351.","journal-title":"N Engl J Med"},{"issue":"11","key":"3099_CR11","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392.","journal-title":"N Engl J Med"},{"issue":"22","key":"3099_CR12","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093\u2013104.","journal-title":"N Engl J Med"},{"issue":"13","key":"3099_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017559","volume":"9","author":"A Chen","year":"2020","unstructured":"Chen A, Stecker E, Warden BA. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9(13): e017559.","journal-title":"J Am Heart Assoc"},{"key":"3099_CR14","doi-asserted-by":"publisher","first-page":"1125576","DOI":"10.3389\/fphar.2023.1125576","volume":"14","author":"M Grymonprez","year":"2023","unstructured":"Grymonprez M, De Backer TL, Bertels X, Steurbaut S, Lahousse L. Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: a nationwide cohort study. Front Pharmacol. 2023;14:1125576.","journal-title":"Front Pharmacol"},{"issue":"10","key":"3099_CR15","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. EP Europace. 2021;23(10):1612\u201376.","journal-title":"EP Europace"},{"issue":"6","key":"3099_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40256-018-0296-x","volume":"18","author":"X Feng","year":"2018","unstructured":"Feng X, Sambamoorthi U, Innes K, LeMasters T, Castelli G, Dwibedi N, et al. Healthcare utilization and expenditures in working-age adults with atrial fibrillation: the effect of switching from warfarin to non-vitamin K oral anticoagulants. Am J Cardiovasc Drugs. 2018;18(6):513\u201320.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"12","key":"3099_CR17","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1185\/03007995.2015.1092124","volume":"31","author":"K Francis","year":"2015","unstructured":"Francis K, Yu C, Alvrtsyan H, Sander S, Ghosh S, Rao Y, et al. Healthcare utilization and costs associated with dabigatran compared to warfarin treatment in newly diagnosed patients with non-valvular atrial fibrillation. Curr Med Res Opin. 2015;31(12):2189\u201395.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"3099_CR18","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12955-017-0705-x","volume":"15","author":"SL Reynolds","year":"2017","unstructured":"Reynolds SL, Ghate SR, Sheer R, Gandhi PK, Moretz C, Wang C, et al. Healthcare utilization and costs for patients initiating Dabigatran or Warfarin. Health Qual Life Outcomes. 2017;15(1):128.","journal-title":"Health Qual Life Outcomes"},{"key":"3099_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-024-02976-1","author":"GYH Lip","year":"2024","unstructured":"Lip GYH, Noxon V, Kang A, Luo X, Atreja N, Han S, et al. Effectiveness and safety in non-valvular atrial fibrillation patients switching from warfarin to direct oral anticoagulants in US healthcare claims. J Thromb Thrombolysis. 2024. https:\/\/doi.org\/10.1007\/s11239-024-02976-1.","journal-title":"J Thromb Thrombolysis"},{"issue":"11","key":"3099_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.42964","volume":"5","author":"D Ko","year":"2022","unstructured":"Ko D, Lin KJ, Bessette LG, Lee SB, Walkey AJ, Cheng S, et al. Trends in Use of Oral Anticoagulants in Older Adults With Newly Diagnosed Atrial Fibrillation, 2010\u20132020. JAMA Netw Open. 2022;5(11): e2242964-e.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"3099_CR21","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245\u201351.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"3099_CR22","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.55730\/1300-0144.5413","volume":"52","author":"JY Zheng","year":"2022","unstructured":"Zheng JY, Li DT, Q\u0131u YG, Huang YX, Xu ZM, Zhao L, et al. CHA2DS2-VASc score as a prognostic indicator in patients with atrial fibrillation undergoing coronary stenting. Turk J Med Sci. 2022;52(4):1103\u201310.","journal-title":"Turk J Med Sci"},{"issue":"5","key":"3099_CR23","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, De Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro heart survey. Chest. 2010;138(5):1093\u2013100.","journal-title":"Chest"},{"issue":"7","key":"3099_CR24","first-page":"488","volume":"17","author":"V Fung","year":"2011","unstructured":"Fung V, Brand RJ, Newhouse JP, Hsu J. Using medicare data for comparative effectiveness research: opportunities and challenges. Am J Manag Care. 2011;17(7):488\u201396.","journal-title":"Am J Manag Care"},{"issue":"2","key":"3099_CR25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10654-018-0415-7","volume":"34","author":"G Li","year":"2019","unstructured":"Li G, Lip GYH, Holbrook A, Chang Y, Larsen TB, Sun X, et al. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. Eur J Epidemiol. 2019;34(2):173\u201390.","journal-title":"Eur J Epidemiol"},{"issue":"11","key":"3099_CR26","first-page":"1116","volume":"24","author":"K Gupta","year":"2018","unstructured":"Gupta K, Trocio J, Keshishian A, Zhang Q, Dina O, Mardekian J, et al. Real-world comparative effectiveness, safety, and health care costs of oral anticoagulants in nonvalvular atrial fibrillation patients in the U.S. Department of defense population. J Manag Care Spec Pharm. 2018;24(11):1116\u201327.","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"3099_CR27","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"CT January","year":"2019","unstructured":"January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation. 2019;140(2):e125\u201351.","journal-title":"Circulation"},{"issue":"5","key":"3099_CR28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS) the task force for the diagnosis and management of atrial fibrillation of the European society of cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373\u2013498.","journal-title":"Eur Heart J"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03099-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03099-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03099-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T08:36:17Z","timestamp":1740645377000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03099-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3099"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03099-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anandkumar Dubey, Amiee Kang, Jenny Jiang, and Dong Cheng are employees of BMS and may hold stock options. Nipun Atreja\u00a0and Melissa Hagan were employees of BMS when the study was conducted. Nipun Atreja is currently affiliated with Immunovant. Melissa Hagan is currently affiliated with BeiGene. Abimbola Michael-Asalu is an employee of STATinMED. Steven Deitelzweig received research and consulting support from Pfizer and BMS.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Since this study did not involve the collection, use, or transmittal of individually identifiable data, Institutional Review Board (IRB) approval was not required. This study only analyzed de-identified data which are a priori exempt from the Federal Policy for the Protection of Human Subjects (1991) and do not meet the identification criteria necessary to be privileged under the Health Insurance Portability and Accountability Act (HIPAA). Both the data and the security of the offices where the data were kept met HIPAA requirements. All authors had permission to access and use the database utilized in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}